Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
15.64
+0.98 (6.68%)
At close: Jul 2, 2026, 4:00 PM EDT
15.96
+0.32 (2.02%)
After-hours: Jul 2, 2026, 7:17 PM EDT
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
976.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 369.49M |
| Arbutus Biopharma | 191.45M |
| Kura Oncology | 71.64M |
| Lexicon Pharmaceuticals | 69.64M |
| Janux Therapeutics | 13.73M |
| Inventiva | 7.94M |
| DBV Technologies | 5.74M |
| Avalo Therapeutics | 59.00K |
DSGN News
- 4 days ago - Design Therapeutics initiates patient dosing in DT-818 trial - TheFly
- 4 days ago - Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - GlobeNewsWire
- 4 weeks ago - Design Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Design Therapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Design Therapeutics Transcript: Status update - Transcripts
- 6 weeks ago - Design Therapeutics Press release: Status update - Filings
- 6 weeks ago - Design Therapeutics Slides: Status update - Filings